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of G Protein–mediated IP3 Signaling Pathway 
in Dystrophin-deﬁ  cient Muscle Cells
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Ludivine Mondin, Elise Mok, Alain Kitzis, Guy Raymond, and Christian Cognard
Institut de Physiologie et Biologie Cellulaires, CNRS UMR 6187, Université de Poitiers, 86022 Poitiers, France
We present here evidence for the enhancement of an inositol 1,4,5-trisphosphate (IP3) mediated calcium signal-
ing pathway in myotubes from dystrophin-defi  cient cell lines (SolC1(−)) as compared to a cell line from the same 
origin but transfected with mini-dystrophin (SolD(+)). With confocal microscopy, we demonstrated that calcium 
rise, induced by the perifusion of a solution containing a high potassium concentration, was higher in SolC1(−) 
than in SolD(+) myotubes. The analysis of amplitude and kinetics of the calcium increase in SolC1(−) and in 
SolD(+) myotubes during the exposure with SR Ca2+ channel inhibitors (ryanodine and 2-APB) suggested the 
presence of two mechanisms of SR calcium release: (1) a fast SR calcium release that depended on ryanodine re-
ceptors and (2) a slow SR calcium release mediated by IP3 receptors. Detection analyses of mRNAs (reverse tran-
scriptase [RT]-PCR) and proteins (Western blot and immunolocalization) demonstrated the presence of the three 
known isoforms of IP3 receptors in both SolC1(−) and SolD(+) myotubes. Furthermore, analysis of the kinetics 
of the rise in calcium revealed that the slow IP3-dependent release may be increased in the SolC1(−) as compared 
to the SolD(+), suggesting an inhibitory effect of mini-dystrophin in this signaling pathway. Upon incubation with 
pertussis toxin (PTX), an inhibitory effect similar to that of the IP3R inhibitor (2-APB) was observed on K+-evoked 
calcium release. This result suggests the involvement of a Gi protein upstream of the IP3 pathway in these stimula-
tion conditions. A hypothetical model is depicted in which both Gi protein and IP3 production could be involved 
in K+-evoked calcium release as well as a possible interaction with mini-dystrophin. Our fi  ndings demonstrate the 
existence of a potential relationship between mini-dystrophin and SR calcium release as well as a regulatory role 
of mini-dystrophin on intracellular signaling.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is a progressive 
disease affecting 1/3,500 male births and   characterized 
by the absence of dystrophin due to a defect in the 
p21 band of the X chromosome (Monaco et al., 1986). 
Dystrophin is a 427-kD cytoskeletal protein normally ex-
pressed at the inner surface of the sarcolemma of muscle 
fi  bers (Hoffman et al., 1987) and associated with a large 
complex of proteins known as the dystrophin-associated 
proteins (DAPs) (Ervasti and Campbell, 1991). In DMD 
patients, the lack of dystrophin leads to muscle degener-
ation and progressive weakness. Mutations of the dystro-
phin gene can also cause another pathology, the milder 
Becker muscular dystrophy (BMD) associated with the 
expression of a truncated 229-kD protein, namely mini-
dystrophin, which lacks 17 units in the central rod do-
main. It has been shown that the small size of the gene 
encoding for this mini-dystrophin protein facilitated its 
expression via retroviral vector and allowed functional 
recovery in mdx mice (Deconinck et al., 1996).
Previous studies have shown association between in-
creased cytosolic calcium and the extensive muscle de-
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generation at late stage DMD (Bodensteiner and Engel, 
1978; Imbert et al., 1995). It has been proposed in dys-
trophic cells that the absence of dystrophin leads to an 
abnormal elevation of the cytosolic resting calcium 
level. However, the mechanism is poorly understood. 
Several authors suggested that dystrophin acts to favor 
the regulation or stabilization of calcium transport 
mechanisms in the sarcolemma (Imbert et al., 1996; 
Vandebrouck et al., 2001). Other studies reported some 
changes in the properties of membrane calcium cur-
rents in human DMD cells (Imbert et al., 2001). Pres-
ently, there is little data concerning a possible role of SR 
Ca2+ in the calcium mishandling observed in dystrophic 
cells (Liberona et al., 1998). Furthermore, modifi  cation 
of the regulation of calcium stores has been suggested 
to be involved in the general calcium disregulation in 172 IP3 Receptors and Dystrophin-deﬁ  cient Cells
mdx mice (Divet and Huchet-Cadiou, 2002; Vande-
brouck et al., 2002).
In skeletal muscle, excitation–contraction coupling 
takes place by release of stored calcium from the SR via 
ryanodine receptors (RYRs). This release is triggered by 
an allosteric signal transmitted to the release channels 
from sarcolemmal voltage sensors, the dihydropyridine 
receptors (DHPRs) (Rios et al., 1991; Ursu et al., 2001; 
Lorenzon et al., 2004). Nevertheless, the inositol 1,4,5-
  trisphosphate receptor (IP3R) family of Ca2+ release chan-
nels, which play a key role in Ca2+ signaling in many other 
mammalian cells (Berridge, 1993; Blondel et al., 1994; 
Bootman et al., 1995; Furuichi and Mikoshiba, 1995), 
is thought to play a role in muscle cells. The process 
of IP3-induced Ca2+ release has been well documented 
in smooth muscle cells (Miyakawa et al., 1999; Patel et al., 
1999; Dyer and Michelangeli, 2001). More controversial, 
however, is the idea that IP3 may modulate EC coupling 
in cardiac muscle (Lipp et al., 2000), which also remains 
poorly understood in skeletal muscle cells. Since the early 
works of Jaimovich and Hidalgo (Hidalgo et al., 1986), 
it is known that skeletal muscle fi  bers possess the basic 
  molecular machinery for a functioning IP3 messenger sys-
tem, including PLC, inositolphosphate phosphatases, IP3 
kinase, and G-proteins (Carrasco and Figueroa, 1995).
In our previous work using a Sol cell line, intrinsically 
lacking dystrophin (Sol8 or SolC1(−)), we had selected 
stable Sol8 subclones, SolD(+), which constitutively ex-
press the BMD mini-dystrophin (Marchand et al., 2004). 
This study showed that myotubes from the SolC1(−) cell 
line exhibited morphological signs of cell death during 
myogenesis in culture, in parallel with an alteration of 
Ca2+ homeostasis. Furthermore, expression of BMD mini-
dystrophin restored sarcolemmal expression and location 
of several members of the DAPs complex and allowed 
these cells to recover an intracellular Ca2+ concentration 
closer to myotubes from mouse primary cell culture.
We have observed that blockade of the IP3 pathway sig-
nifi  cantly reduced calcium release in SolC1(−). Hence, 
the aim of the present study was to examine calcium tran-
sients recorded on SolC1(−) and SolD(+) myotubes (Sol 
myotubes) during excitation by depolarization with a high 
potassium solution. RT-PCR, Western blot, and immuno-
cytochemistry analyses have been performed to investigate 
the expression pattern of IP3R proteins in both myotubes, 
revealing the presence of a potential IP3-dependent cal-
cium release system. Experiments conducted in this work 
demonstrate a modulator effect of mini-dystrophin (via a 
Gi protein) on IP3-dependent calcium release.
MATERIALS AND METHODS
Cell Lines
Sol8 myogenic cell line (a gift from I. Martelly, University of Paris 
XII, Creteil, France) was derived from the Sol8 cell line originally 
obtained from primary culture of normal C3H mouse soleus 
  muscle (Mulle et al., 1988). The method for obtaining cell lines 
(SolC1(−) and SolD(+)) was described elsewhere (Marchand 
et al., 2004). In brief, after several steps of cloning, a dystrophin-
defi  cient cell line was obtained, named SolC1(−). The SolD(+) 
cell line was obtained by transfection of the SolC1(−) cell line 
with a retrovirus encoding for mini-dystrophin (229 kD). SolC1(−) 
and SolD(+) cell lines (“Sol” cell lines in the following text) main-
tain a high ability to fuse and form myotubes. Cells were seeded 
on gelatin-coated glass coverslips in plastic dishes. Myoblasts were 
grown to  80% of confl  uence in HamF12/DMEM (1:1) medium 
supplemented with 10% FCS, 1% l-glutamine, and 1% antibiot-
ics. To induce differentiation, the growth medium was changed to 
a fusion medium (DMEM supplemented with 2% heat-inactivated 
horse serum, insulin [10 μg/ml, Sigma-Aldrich]), 1% l- glutamine, 
and 1% antibiotics). Experiments were performed at the stage of 
F+4 for SolC1(−) and SolD(+) myotubes.
RT-PCR
Reverse Transcription.  Total cellular RNA was extracted using 
  RNABle kit (Eurobio). RNAs (10 μL) were reverse transcribed in 
a 25-μl reaction mixture consisting of fi  rst strand buffer (25 mM 
Tris, pH 8.3, 37.5 mM KCl, 1.5 mM MgCl2), 10 mM DTT, 1 mM 
each dNTP, 2.4 mg of random hexamers, 40 U RNase inhibitor 
(RNA guard, Amersham Biosciences), and 400 U M-MLV reverse 
transcriptase (GIBCO-BRL). Reverse transcription was performed 
at 37°C for 60 min followed by 2 min at 100°C. The solution was 
then diluted twice in water.
Real-time PCR. The 15-μl reaction mixture contained 7.5μl 2× 
Taqman Universal Master Mix (Applied Biosystems), 5 μl of RT 
products, and appropriate primers and probes (900 nM and 200 
nM, respectively). All probes contained a 3′ TAMRA (6-carboxy-
tetramethylrhodamine) quencher dye and were labeled at the 5′ 
end with a FAM (6-carboxyfl  uorescein) reporter fl  uorescent dye. 
Probes and primers are described in Table I.
Amplifi   cation was performed at 50°C for 2 min, 95°C for 
10 min, followed by 40 cycles at 95°C (15 s) and 60°C (1 min). Re-
actions were performed in MicroAmp optical 96-well reaction 
plates (Applied Biosystems) using an ABI PRISM 7700 sequence 
detection system (Applied Biosystems). All measurements were 
normalized to the mitochondrial ribosomal protein S6 (Mrps6, 
an endogenous control) to account for the variability in the initial 
concentration and quality of the total RNA.
SDS-PAGE and Immunoblot
Total cell lysates were obtained from SolC1(−) and SolD(+) myo-
tubes. Cells were washed with PBS and solubilized at 4°C in lysis 
TABLE I
Description of Probes and Primers Used for RT-PCR
IP3R-1
Forward primer 5′-TGG-CAG-AGA-TGA-TCA-GGG-AAA-3′
Reverse primer 5′-GCT-CGT-TCT-GTT-CCC-CTT-CAG-3′
Probe 5′-CCA-TGT-CCC-TGG-TCA-GCA-GCG-A-3′
IP3R-2
Forward primer 5′-GCT-CAG-ATG-ATC-ACG-GAG-AAG-3′
Reverse primer 5′-ATC-TCA-TTT-TGC-TCA-CTG-TCA-CCT-3′
Probe 5′-CGA-GCC-ATG-TCA-CTT-GTC-AGC-AAC-G-3′
IP3R-3
Forward primer 5′-TCA-TTG-TAC-TGG-TCC-GAG-TCA-AGA-3′
Reverse primer 5′-GCG-GGA-ACC-AGT-CCA-GGT-3′
Probe 5′-CCG-GCC-CCG-AGA-GCT-ATG-TGG-CT-3′Balghi et al. 173
buffer containing 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 100 mM 
NaCl, 1% Triton X-100 and protease inhibitors (20 μM leupeptin, 
0.8 μM aprotinin, 10 μM pepstatin, and 2 mM 4-[2-aminoethyl]-
benzenesulfonyl fl  uoride). Cells were scraped from the dishes 
and, after incubation on ice for 30 min, clarifi  ed by centrifuga-
tion at 15,000 g for 5 min at 4°C. Total proteins were quantifi  ed 
using the Bio-Rad Laboratories protein assay reagent and 30 μg of 
protein was loaded onto an SDS-PAGE apparatus. Proteins were 
separated in 5% polyacrylamide gels and electrophoretically 
transferred from gels to a 0.20-μm pore nitrocellulose membrane 
(Sartorius) using a Miniprotean III electroblotter (Bio-Rad Labo-
ratories) for 2 h at 4°C. Immunoblots were washed in PBS con-
taining 0.1% Tween-20 (PBS-Tween) and then probed overnight 
at 4°C with primary antibodies: a rabbit polyclonal antibody raised 
against IP3R-1 (Affi  nity Bioreagents), a goat polyclonal antibody 
raised against IP3R-2 (1:1,000; Santa Cruz Biotechnology), and a 
mouse monoclonal antibody against IP3R-3 (1:1,000; BD Trans-
duction Laboratories) in PBS-Tween. Membranes were washed 
and incubated for 1 h at 4°C with the secondary antibodies: either 
horseradish peroxidase–conjugated (HRP) anti-mouse (1:3,000; 
Jackson ImmunoResearch Laboratories) or HRP-conjugated anti-
goat (1:2,000; Santa Cruz Biotechnology), or HRP-conjugated 
anti-rabbit (1:3,000; Amersham Biosciences). Bound antibodies 
were detected using enhanced luminol and oxidizing reagents as 
specifi  ed by the manufacturer (ECL; Amersham Biosciences).
Immunological Staining
Cultured cells were stained by an indirect immunofl  uorescence 
method. Cells were rinsed in TBS (20 mM Tris base, 154 mM 
NaCl, 2 mM EGTA, 2 mM MgCl2, pH 7.5) and fi  xed with either 
4% paraformaldehyde (PFA) in TBS for 20 min or methanol 
(stored at −20°C) for 6 min, at room temperature. Only samples 
fi  xed with PFA were permeabilized with TBS/0.5% Triton X-100 
for 10 min. Affi  nity Bioreagents supplied the anti–IP3R-1 (the 
same was used for Western blot) and the anti–IP3R-2 epitope-
  affi  nity purifi  ed polyclonal antibodies (1:250, PA1-901; and 1:100, 
PA1-904, respectively). No commercial anti–IP3R-3 antibody was 
available for us to perform immunolocalization of this isotype. 
Cells were incubated with primary antibodies in TBS/1% BSA 
(Sigma-Aldrich) for 1 h. After washing in TBS, cells were incu-
bated for 30 min with the secondary antibody rhodamine red-
X–conjugated goat anti-rabbit (1:200; Jackson ImmunoResearch 
Laboratories). Samples were mounted in Vectashield Medium 
(Vector Laboratories Inc.) for viewing with a confocal laser scan-
ning microscope using a Bio-Rad Laboratories MRC 1024. Immu-
nostaining images were processed (no gamma adjustment) and 
assembled in Powerpoint 2000.
Confocal Ca2+ Measurement
Ca2+ activity was recorded by confocal laser scanning microscopy 
using a Bio-Rad Laboratories MRC 1024 equipped with a 15 mW 
Ar/Kr gas laser. The confocal unit was attached to an inverted 
microscope (Olympus IX70). Fluorescence signal collection was 
performed through the control software Lasersharp 3.2 (Bio-Rad 
Laboratories). Myotubes were loaded with 3 μM fl  uo-4 acetoxy-
methyl (AM) ester (Molecular Probes) for 15 min at room tem-
perature (20°C) in a resting solution (130 mM NaCl, 5.4 mM KCl, 
2.5 mM CaCl2, 0.8 mM MgCl2, 10 mM HEPES, and 5.6 mM 
  glucose, pH 7.4).
The fl  uorescent images were visualized through the X60 oil 
  immersion objective and collected every 300 ms (256 × 256). 
  Regions of interest (ROIs) have been selected in myotubes, and 
fl  uorescence transients from these ROIs were analyzed. Myotubes 
exposed to high K+ solution (47 mM KCl) were depolarized by an 
immediate change of solution by perifusion inducing global Ca2+ 
variations. Ryanodine (Sigma-Aldrich) was incubated at 100 μM 
for 10 min to inhibit RYRs. For IP3 inhibition studies, myotubes 
were incubated for 30 min in 50 μM 2-APB (Calbiochem) or 
for 20 min in the presence of 10 μM U73122 (Sigma-Aldrich). 
PTX (Calbiochem) was incubated at 1 μg/ml for 1 h.
Calcium Transient Processing
Fluorescence transients from ROIs in Fluo-4–loaded myotubes 
were analyzed with a computer program developed in our labo-
ratory under IDL 5.3 structured language on a PC computer. 
Five parameters were extracted from analyzed curves for the 
characterization of calcium release amplitude and kinetics. 
These parameters were amplitude of the signal (normalized dif-
ference between the fl  uorescence of the peak and the back-
ground), area under the curve (area, in arbitrary units [A.U.s]) 
of the normalized curve, time to peak (TTP, in s), mean deriva-
tive at the beginning of the increase (increase slope, in A.U.s), 
and the half decay time (HD, in s). All these parameters were 
represented in histograms as relative values to control conditions 
in SolD(+) set at 1.0.
Statistical Analysis
All results are expressed as mean ± SEM of n observations. Sets 
of data were compared using Student’s t test. All statistical tests 
Figure 1.  Examples of K+-evoked calcium increase in SolC1(−) 
and SolD(+) myotubes: effects of ryanodine and 2-APB. Fluores-
cence rise from fl   uo-4–loaded myotubes was recorded as de-
scribed in MATERIALS AND METHODS. During the recording, 
high K+-containing solution (47 mM) was perifused near the ana-
lyzed myotubes (black arrows), and measurements were stopped 
after recovery to basal levels. (A) Representative examples of 
K+-evoked calcium increase in a SolC1(−) and a SolD(+) myotube 
in control conditions. Examples of K+-evoked calcium increase in 
the presence of ryanodine (+rya, 100 μM) or 2-APB (+2-APB, 
50 μM) in SolC1(−) (B) and in SolD(+) (C). The gray curve rep-
resents the sum of the curve in the presence of ryanodine and the 
curve in the presence of 2-APB in SolC1(−) (B) and in SolD(+) 
(C). (D) Fluorescence signals obtained in SolC1(−) and SolD(+) 
myotubes with a combined incubation with ryanodine and 2-APB 
(+rya +2-APB).174 IP3 Receptors and Dystrophin-deﬁ  cient Cells
were performed using GraphPad Prism version 3.0 for Windows 
(GraphPad Software).
RESULTS
Calcium Increase Induced by Depolarizing Solution 
in SolC1(−) and SolD(+) Myotubes
Previous studies provided evidence for at least two 
phases in the calcium rise observed in cultured skeletal 
muscle cells exposed to a high potassium solution 
  (Jaimovich et al., 2000; Powell et al., 2001). According 
to their kinetic properties, these two phases were identi-
fi  ed as slow and fast calcium signals. In these works, the 
slow calcium signal was eliminated in the presence of 
IP3 inhibitors while the fast signal was abolished with 
ryanodine, showing also that the calcium increase ob-
served in this stimulation condition was mainly originat-
ing from SR release.
We investigated here intracellular calcium increase 
during stimulation with a similar extracellular potas-
sium solution (47 mM KCl) in fl  uo-4–loaded SolC1(−) 
(without dystrophin) and SolD(+) myotubes (express-
ing mini-dystrophin). Fig. 1 displays examples of fl  uo-
rescence recordings in both cell types and in the 
presence of SR Ca2+ channels inhibitors. Upon superfu-
sion with high potassium solution, in control conditions, 
all myotubes exhibited an intracellular calcium increase 
(K+-evoked calcium increase) followed by a slow recov-
ery but rarely showed a biphasic pattern (Fig. 1 A). Fur-
thermore, the amount of released calcium was higher in 
SolC1(−) myotubes than in SolD(+) myotubes.
To understand the pathways of K+-evoked calcium re-
lease in the Sol myotubes, we tested the effect of ryano-
dine and 2-APB separately in SolC1(−) (Fig. 1 B) and 
in SolD(+) (Fig. 1 C) as well as together in both myo-
tube types (Fig. 1 D). Ryanodine, known to inhibit RYRs 
at high concentrations (preincubation: 100 μM for 
15 min), induced a weak and slow K+-evoked calcium 
increase in both SolC1(−) and SolD(+) myotubes 
(Fig. 1, B and C). Furthermore, the remaining transients 
in the presence of ryanodine as illustrated here were 
seen in >80% of the cells in SolC1(−) and in 50% of 
SolD(+). No signal was seen in all other tested cells. 
This difference between cells suggests a stronger sensi-
tivity to ryanodine in SolD(+) for the K+-evoked cal-
cium release. Interestingly, the slow phase observed 
here closely resembled that initially presented in the 
study from Powell et al. (2001). To investigate the in-
volvement of IP3Rs in K+-evoked calcium release, the 
direct inhibitor of IP3 receptors, 2-APB, was also tested 
(preincubation: 50 μM for 30 min) on K+-evoked cal-
cium release in SolC1(−) (Fig. 1 B) and in SolD(+) 
(Fig. 1 C). In both cell types, the amplitude and amount 
of calcium release were notably reduced. Moreover, in 
both myotubes, calcium increase kinetics were not 
modifi  ed by 2-APB while the recovery of fl  uorescence 
was faster than in control conditions. Finally, preincuba-
tion with both inhibitors together nearly abolished cal-
cium release in Sol myotubes (Fig. 1 D).
Thus, although SolC1(−) and SolD(+) myotubes did 
not show a biphasic K+-evoked calcium release, the inhi-
bition of RYRs revealed a slow phase of calcium release 
while the blockade of IP3Rs, showed a fast phase. Both 
inhibitions together led to a nonsignifi  cant calcium in-
crease, suggesting that this response mainly depends on 
the SR release in SolC1(−) and SolD(+) myotubes.
A reconstructed release curve obtained by adding to-
gether the curve in the presence of ryanodine and the 
Figure 2.  Amplitude and “area under the curve” parameters 
from K+-evoked calcium increases in Sol cell lines: effects of ry-
anodine and 2-APB. Large-scale analysis of K+-evoked fl  uores-
cence rises has been realized to compare them in the two myotube 
types and in the presence of SR Ca2+ channel inhibitors. All these 
parameters were represented in histograms as relative values to 
control conditions in SolD(+) set at 1.0. Parameters have been 
automatically measured with a computer program developed un-
der IDL 5.3 (Fig. 3, inset). (A) Histogram representing the rise 
amplitude (∆F/F0) in SolC1(−) (white bars) and SolD(+) (black 
bars) in controls and with inhibitors (same incubation conditions 
as in Fig. 1). The number of analyzed myotubes is given in histo-
gram bars. (B) Histogram representing the “area under the curve” 
parameter measured on curves obtained in SolC1(−) (white 
bars) and SolD(+) (black bars). Each bar graph corresponds 
to the mean value ± SEM obtained for each type of myotube. 
ns, not signifi  cantly different. ***, P < 0.001; **, 0.001 ≤ P < 0.01; 
*, 0.01 ≤ P < 0.05 (Student’s unpaired t test).Balghi et al. 175
curve in the presence of 2-APB is presented in Fig. 1 B 
for SolC1(−) and in Fig. 1 C for SolD(+) myotubes (in 
gray). This reconstructed curve corresponds to the sum 
of both the ryanodine-insensitive and the 2-APB–
  insensitive SR release components. In SolC1(−), the 
sum of the two release components was clearly weaker 
than the control (Fig. 1 B), suggesting a positive interac-
tion between the two SR release mechanisms. In SolD(+), 
the difference between the sum of the two release com-
ponents and the control was less obvious (Fig. 1 C).
K+-evoked Calcium Increase Depends on Two 
Release Components
To explore the two release phases in both cell lines, 
large-scale analysis has been performed on K+-evoked 
calcium recordings. Two parameters have been mea-
sured to investigate calcium releases: amplitude (nor-
malized difference between the fl   uorescence of the 
peak and the background, ∆F/F0) and area under the 
curve (A.U.s) (Fig. 2). To simplify comparisons between 
myotube types and inhibitor exposure, the following re-
sults will be given relative to control conditions with 
SolD(+) set at 1.0. As compared with SolD(+) (black 
bars), SolC1(−) myotubes (white bars) displayed in-
creased calcium with respect to amplitude (Fig. 2 A) 
and area under the curve (Fig. 2 B).
In the presence of ryanodine, calcium rise was re-
duced in SolC1(−) and SolD(+) as shown by a reduc-
tion in amplitude (76% and 66% reduction, respectively; 
Fig. 2 A) and area under the curve (97% and 95% of re-
duction, respectively; Fig. 2 B). Nevertheless, no signifi  -
cant difference in calcium release was found in the two 
cell types incubated with ryanodine (with respect to 
∆F/F0 and area under the curve). These results suggest 
the presence of a calcium release mechanism insensi-
tive to ryanodine, which is more apparent in SolC1(−), 
during the excitation–calcium release coupling.
Large-scale analysis of calcium rise in SolC1(−) and 
SolD(+) myotubes also demonstrated that 2-APB expo-
sure signifi  cantly reduced calcium increase amplitude 
(61% and 37% of reduction, respectively; Fig. 2 A) and 
area under the curve (75% and 59% reduction, respec-
tively; Fig. 2 B). This result suggests that calcium release 
in SolC1(−) myotubes was more affected by the IP3R 
inhibitor versus SolD(+) myotubes. It is also worth not-
ing that in control conditions, there was a signifi  cant 
Figure 3.  Kinetics parameters from K+-evoked calcium increases 
in Sol cell lines: effects of ryanodine and 2-APB. Inset, measure-
ment of amplitude and kinetic parameters. All these parameters 
were automatically measured with a computer program devel-
oped in our laboratory under IDL 5.3 structured language. 
F0, basal fl  uorescence obtained from averaged fl  uorescence before 
high K+ stimulation. After stimulation, a maximum value is de-
tected in the curve and fl  uorescence around this value was aver-
aged, giving the F value. Amplitude was determined as F−F0/F0 
(∆F/F0). Area under the curve (area, A.U.s.) was calculated in in-
tegrating the curve. Time to peak (TTP, in seconds) was deter-
mined as the time between 5% of F and F during the increase. 
Half decay time (HD, in seconds) was determined as the time 
between F and F/2 during the decay. Increase slope (in A.U/s) 
was determined in averaging the derivative of the curve where it 
was the maximum during the increase, corresponding to the 
  beginning of the increase. All these parameters were represented 
in histograms as relative values to control conditions in SolD(+) 
set at 1.0. (A) Histogram representing the “time to peak” parame-
ter in SolC1(−) (white bars) and SolD(+) (black bars) in con-
trols and with inhibitors. The number of analyzed myotubes is 
given on histogram bars. Histograms representing the “increase 
slope” (B) and the “half decay” (C) parameters. Each bar 
graph corresponds to the mean value ± SEM obtained for each 
type of myotubes. ns, not signifi  cantly different. ***, P < 0,001; 
**, 0.001 ≤ P < 0.01; *, 0.01 ≤ P < 0.05 (Student’s unpaired t test).176 IP3 Receptors and Dystrophin-deﬁ  cient Cells
difference in calcium release between SolC1(−) and 
SolD(+), whereas with 2-APB application, calcium re-
lease was similar between the two myotube types. Further-
more, combination of ryanodine and 2-APB further 
reduced calcium release in both myotubes (>95% re-
duction; Fig. 2, A and B).
Identiﬁ  cation of Both Fast and Slow Components 
in K+-evoked Calcium Increase
Kinetic parameters, derived from the fl  uorescence sig-
nals, were examined to further compare the calcium 
release pattern in responding SolC1(−) and SolD(+) 
myotubes (Fig. 3). The parameters defi  ned here were 
the time to peak (TTP, in seconds) (Fig. 3 A), the mean 
derivative during the increase (increase slope [IS], 
A.U.s−1) (Fig. 3 B), and the half decay (HD, in seconds) 
of fl  uorescence (Fig. 3 C).
In our experiments, the TTP and IS parameters pro-
vided information mainly on mechanisms that initiate 
calcium release. Fig. 3 A shows that in control condi-
tions, TTP values were not signifi  cantly different be-
tween SolC1(−) and SolD(+) myotubes. This suggests 
that the mechanism involved in the triggering of SR 
calcium release, during depolarization, might not be 
different between SolC1(−) and SolD(+) myotubes. 
TTP measured in the presence of ryanodine was dra-
matically increased in both myotubes (375% and 489% 
increase, respectively; Fig. 3 A). These quantitative re-
sults raise the assumption that a slow rise in calcium in-
crease, independent of RYR activation, could occur as 
a secondary calcium release. As compared with the 
  controls, exposure with 2-APB did not signifi  cantly 
change the TTP parameter, suggesting that the fi  rst 
steps of this K+-evoked calcium release may not be de-
pendent on IP3 receptors. Kinetic parameters from 
in  cubation of ryanodine and 2-APB together are 
  presented in Fig. 3 for a complete analysis. However, 
because of the weak calcium release revealed in these 
conditions, we did not further study the effect of incu-
bation with ryanodine and 2-APB together. Because 
TTP depends on amplitude and because other mecha-
nisms of Ca2+ buffering and SR uptake are activated 
when the intracellular calcium concentration is in-
creased, we measured the slope of calcium rise (IS) at 
the beginning of the increase, when the opening of 
SR Ca2+ channels is the main process that leads to in-
creased calcium concentrations. This parameter is in-
creased in control SolC1(−) as compared with control 
SolD(+) myotubes (Fig. 3 B) and is signifi  cantly re-
duced in the presence of ryanodine in both cells (92% 
and 88% reduction, respectively, in SolC1(−) and 
SolD(+)). The inhibitory effect during IP3R blockade 
(2-APB) was weaker than with ryanodine exposure and 
leads to a similar decrease (versus control) in the IS 
parameter in both SolC1(−) and SolD(+) (35% and 
33% decrease, respectively).
Fig. 3 C presents the half decay (HD) parameter, 
which represents the recovery of fl  uorescence to the 
  basal level in treated and untreated Sol myotubes. 
In control conditions, the time to recover the basal level 
of fl  uorescence was longer in SolC1(−) than in SolD(+) 
myotubes, showing that the calcium rise in SolC1(−) 
myotubes lasted longer than in SolD(+) myotubes. 
When RYRs were inhibited with ryanodine, the HD was 
longer in both myotubes (78% and 80% increase in 
SolC1(−) and SolD(+), respectively; Fig. 3 C). More-
over, when calcium release from IP3Rs was blocked with 
2-APB, the HD in SolC1(−) and SolD(+) myotubes was 
decreased (59% and 40% of reduction in SolC1(−) and 
SolD(+), respectively), leading to a faster recovery of 
fl  uorescence, particularly in SolC1(−).
Taken together, these results suggest that IP3Rs are 
involved in K+-evoked calcium release in both SolC1(−) 
and SolD(+) myotubes. The analysis of kinetic parameters 
Figure 4.  Expression of IP3Rs in SolC1(−) and SolD(+) myo-
tubes. RT-PCR–based analysis of IP3R-1 (A), IP3R-2 (B), and 
IP3R-3 (C) mRNA for 40 cycles. S6 ribosomal mRNA was used as 
an internal standard. Relative mRNA expression levels of IP3R-1, 
IP3R-2, and IP3R-3 was compared with S6 ribosomal mRNA 
  expression. Expression of IP3R isoforms in SolC1(−) myotubes 
were compared with normalized SolD(+) one. Each bar graph 
corresponds to the mean value ± SEM obtained for n  = 4 
(n number of experiments). ns, not signifi  cantly  different. 
***, P < 0,001; **, 0.001 ≤ P < 0.01; *, 0.01 ≤ P < 0.05 (Stu-
dent’s unpaired t test).Balghi et al. 177
permitted us to identify a fast (with 2-APB exposure) 
and a slow (with ryanodine exposure) component in 
K+-evoked calcium increase—the fast component be-
ing mediated by RYRs and the slow component being 
mediated by IP3Rs. Interestingly, both kinetic and am-
plitude parameters suggest that the slow component is 
enhanced in SolC1(−) myotubes where dystrophin is 
absent. To determine whether differences in calcium 
signaling could be attributed to the IP3 signaling path-
way, we then examined the presence of IP3 receptors in 
Sol myotubes.
Expression and Localization of IP3Rs
Three different isoforms of IP3Rs are known to be pre-
sent in skeletal muscle cells (De Smedt et al., 1997). 
IP3R-1 was demonstrated to be the minor form in skele-
tal muscle and in the Sol8 cell line; IP3R-2 is highly pre-
sent in skeletal muscle, and IP3R-3 is the major isoform 
in the Sol8 cell line. mRNA expression of IP3R isoforms 
was examined in SolC1(−) and SolD(+) myotubes with 
quantitative RT-PCR. Fig. 4 shows that mRNA from 
IP3R-1 (Fig. 4 A), IP3R-2 (Fig. 4 B), and IP3R-3 (Fig. 4 C) 
was detected in both SolC1(−) and SolD(+) myotubes 
with no highly signifi  cant differences between SolC1(−) 
and SolD(+) for the three isotypes.
Expression of the IP3R proteins has also been investi-
gated in SolC1(−) and SolD(+) myotubes with West-
ern blot (Fig. 5 A). These qualitative experiments clearly 
demonstrated the presence of IP3R-1, IP3R-2, and IP3R-3 
proteins in both SolC1(−) and SolD(+) myotubes.
Previous studies (Salanova et al., 2002) have shown 
that IP3Rs are localized in the longitudinal SR, which is 
the main site of localization of the SERCA pumps, en-
suring the Ca2+ uptake mechanism. In cardiac muscle, 
the immunolocalization of RYRs and IP3Rs indicated 
that the IP3R-2 colocalized with part of the junctional 
RYR-2 (Lipp et al., 2000; Mackenzie et al., 2002). In our 
work, immunostaining experiments have been con-
ducted in order to localize IP3R-1 and IP3R-2 in Sol 
  myotubes (Fig. 5 B). Similar to what was observed in 
primary mouse cultures (Powell et al., 2001), a clear 
staining of IP3R-1 was found in SolC1(−) myotubes in 
the nuclear envelope region, as well as in the myoplasm 
(Fig. 5 B, a). In SolD(+) myotubes (Fig. 5 B, c), IP3R-1 
was also localized in the nuclear envelope region but 
the staining was fainter than in SolC1(−) and a periph-
eral staining was also observed. For both SolC1(−) and 
SolD(+) myotubes, IP3R-2 was never found in the nu-
clear envelope region. In SolC1(−) (Fig. 5 B, b) and 
SolD(+) (Fig. 5 B, d), IP3R-2 showed a peripheral and 
fully cytoplasmic localization, and, as indicated with 
white arrows, striated staining pattern appeared at this 
differentiation stage (4 d in differentiation medium). 
These qualitative data demonstrate that IP3 receptors 
are expressed in SolC1(−) and SolD(+) myotubes. 
They also indicate localization of IP3R-1 near the 
  nuclear envelope in both cells and a myoplasmic local-
ization of IP3R2. Furthermore, because of the striated 
staining pattern observed in both myotube types, one 
can postulate that IP3R-2 is localized near the structures 
organized in striations (contractile proteins or SR) that 
take place at this differentiation stage in a skeletal mus-
cle cell. Unfortunately, we were not able to localize the 
third isoform with the available IP3R-3 antibodies.
Figure 5.  Determination and immunolocalization of the expres-
sion pattern of IP3R proteins. (A) Western blot analysis of IP3R-1 
(a), IP3R-2 (b), and IP3R-3 (c), respectively, in SolC1(−) and 
SolD(+) myotubes. 30 μg protein from each type of myotube was 
separated on 5% SDS-PAGE, transferred onto a pore nitrocellu-
lose membrane, and processed for Western blot analysis with spe-
cifi  c antibodies. The 220-kD band corresponded to the molecular 
weight of the myosin protein. (B) IP3R isoform immunolabeling 
in SolC1(−) and SolD(+) myotubes was observed with laser scan-
ning confocal microscopy. IP3R-1 and IP3R-2 localizations were 
detected using polyclonal antibodies, PA1-901 and PA1-904, re-
spectively. IP3R-1 staining is localized in the nuclear envelope re-
gion and in the cytoplasm in SolC1(−) (a) and in SolD(+) (c) 
myotubes. IP3R-2 showed a peripheral and fully cytoplasmic local-
ization and, as indicated with white arrows, striated staining pat-
tern appeared at this differentiation stage in SolC1(−) (b) and 
SolD(+) (d) myotubes. Bars, 25 μm.178 IP3 Receptors and Dystrophin-deﬁ  cient Cells
These above data are in agreement with the inhibi-
tory effects of 2-APB during K+-evoked calcium release 
in Sol myotubes, indicating the presence of an IP3-
  mediated system of calcium release in both SolC1(−) 
(lacking dystrophin) and SolD(+) (expressing mini-
dystrophin) myotubes.
Effects of PTX
The skeletal muscle fi  ber possesses the basic molecular 
machinery for a functioning IP3 messenger system, in-
cluding PLC, inositolphosphate phosphatases, IP3 ki-
nase, and G proteins (Carrasco and Figueroa, 1995). 
The IP3 pathway involves PLC activation that catalyzes 
the hydrolysis of phosphoinositol 4,5 bisphosphate 
(PIP2), producing diacylglycerol and IP3. Recent inves-
tigations have shown that a Gi protein could be in-
volved in Ca2+ release induced by depolarization via 
the activation of PLC (Araya et al., 2003). We observed 
with the use of a PLC inhibitor (U73122) a signifi  cant 
decrease of K+-evoked calcium release in Sol myotubes 
(unpublished data). To test the involvement of a G pro-
tein in K+-evoked calcium release, we tested the effect 
of PTX, known to inactivate several G proteins via ADP-
ribosylation of their α subunits (Lampe et al., 2001), 
on depolarization-induced Ca2+ transients (Fig. 6). Fig. 
6 A shows an example of K+-evoked calcium increase 
obtained in SolC1(−) myotubes in the presence of 
1 μg/ml PTX. PTX decreased Ca2+ release amplitude 
and modifi  ed Ca2+ release kinetics in SolC1(−) myo-
tubes. Amplitude and kinetic parameters have been 
measured in a large-scale analysis to examine the 
  inhibitory effect of PTX (Fig. 6, B–F). PTX signifi  cantly 
reduced the amplitude (Fig. 6 B) and the area under 
the curve (Fig. 6 C) of K+-evoked calcium release (63% 
and 69% decrease, respectively) in SolC1(−) (white 
bars) and to a lesser extent (44% and 41% decrease, 
respectively) in SolD(+) myotubes (black bars). More-
over, as with 2-APB, PTX did not modify time to peak in 
both myotubes (Fig. 6 D). Also, PTX showed a similar 
decrease in the increase slope (Fig. 6 E) as shown with 
2-APB. PTX also decreased the half decay in SolC1(−) 
(45%) and in SolD(+) (46%) myotubes (Fig. 6 F). 
Thus, exposure with either 2-APB or PTX led to the 
same pattern of calcium release kinetics. These results 
favor the involvement of a Gi protein acting upstream 
of an IP3-mediated K+-evoked calcium release. Further-
more, despite the differences between SolC1(−) and 
SolD(+) in K+-evoked calcium rise, application of both 
2-APB and PTX led to similar patterns of release in 
both myotube types.
Taken together, these data demonstrate an involve-
ment of the IP3 pathway in Sol myotubes after mem-
brane depolarization as well as an overactivation of the 
Gi protein–dependent pathway in myotubes lacking 
dystrophin as compared with cells in which mini-
  dystrophin has been introduced.
DISCUSSION
In this work, we performed experiments on two types 
of myotubes originating from the same Sol8 cell line: 
(1) dystrophin-deficient myotubes, SolC1(−), and 
Figure 6.  Effect of PTX on K+-evoked calcium increases in Sol cell lines. (A) Representative examples of K+-evoked calcium increase 
in a SolC1(−) in control conditions and in the presence of PTX (+PTX, 1 μg/ml). Histograms representing the amplitude (∆F/F0) 
(B) in SolC1(−) (white bars) and SolD(+) (black bars), the “area under the curve” parameter (C), time to peak (s) (D), increase slope 
(E), and half decay (F) in controls and with PTX exposure. The number of analyzed myotubes is given on histogram bars in B. ns, not 
signifi  cantly different. ***, P < 0,001; **, 0.001 ≤ P < 0.01; *, 0.01 ≤ P < 0.05 (Student’s unpaired t test).Balghi et al. 179
(2)   myotubes transfected to express the BMD mini-
  dystrophin, SolD(+). This mini-dystrophin restoration 
allows the readdressing of members of the DAP com-
plex and the recovery of intracellular Ca2+ levels similar 
to those observed in myotubes from mouse primary cell 
culture (Marchand et al., 2004). Furthermore this 
model allows the physiological exploration of two cellu-
lar systems with the only difference being the presence 
(or not) of mini-dystrophin.
We provided here evidence that K+-evoked calcium 
rise was very different between these two cell types and 
these differences were almost abolished with addition 
of IP3 pathway inhibitors. RT-PCR, Western blot, and 
immunocytochemistry analyses demonstrated the pres-
ence of the three IP3R isoforms in both myotubes and 
subsequently the presence of IP3-dependent release 
machinery. Furthermore, experiments with the aim to 
“dissect” K+-evoked calcium rise by means of SR calcium 
release channel inhibitors revealed two types of release: 
(1) a fast release that depended on RYRs and (2) a slow 
release that was mediated by IP3Rs. The main differ-
ence between SolC1(−) and SolD(+) was a higher 
IP3R-dependent component in SolC1(−). In these 
stimulation conditions, the presence of mini-dystrophin 
seemed to have an inhibitory effect on IP3-dependent 
pathway probably through modulation of a Gi protein.
Involvement of Two Excitation–Calcium Release Processes
The excitation–contraction coupling system in skeletal 
muscle involving DHPRs/RYRs has been largely investi-
gated (Cognard et al., 1990, Franzini-Armstrong and 
Kish, 1995; Protasi et al., 2002). In our experiments, the 
use of high concentration ryanodine did not completely 
abolish Ca2+ release in SolC1(−) and SolD(+) myo-
tubes, suggesting a component of release independent 
of RYRs. A previous study performed on dyspedic mus-
cle myotubes, which do not express RYR isoforms and 
lack excitation–contraction coupling, demonstrated the 
absence of a fast component of calcium release but the 
presence of a slow IP3-dependent calcium release com-
ponent, particularly in the nucleus (Estrada et al., 
2001). This study along with others from Jaimovich’s 
group (Jaimovich et al., 2000; Powell et al., 2001), using 
primary cultures from rat and mouse muscle, suggest 
that skeletal muscle cells in development display a sig-
nifi  cant calcium release mechanism from IP3Rs after 
membrane depolarization. In our work, although we 
did not observe a biphasic K+-evoked calcium rise, con-
siderable differences in kinetics, with inhibitor expo-
sure, strongly support the presence of two processes of 
excitation–calcium release coupling in Sol cells. Experi-
ments with a K+ perfusion system at a lower rate fre-
quently displayed two more phases in the K+-evoked 
calcium rise (unpublished data), suggesting that the 
rate of membrane depolarization plays a role in the sep-
aration of these two phases.
IP3 Inhibitors Reduced Differences in K+-evoked Calcium 
Rise between SolC1(−) and SolD(+) Cells
Our fi   rst observation was that depolarization of 
  dystrophin-defi  cient myotubes (SolC1(−)) induced a 
larger intracellular calcium increase as compared with 
the SolD(+) (expressing mini-dystrophin). This suggests 
that mini-dystrophin expression could play a regulatory 
role in calcium release during cell excitation. Moreover, 
exposure to IP3 inhibitors led to a higher decrease of 
K+-evoked calcium release in SolC1(−) as compared 
with SolD(+), and the pattern of release obtained in 
these conditions was similar between the two cells. This 
suggests that the presence of mini-dystrophin could be 
related to the specifi   c reduction of IP3R-dependent 
K+-evoked calcium release. One can then hypothesize 
that the enhanced calcium release in dystrophin-defi  cient 
myotubes could be due for the most part to the activation 
of the IP3-dependent release process that is missing or 
depressed in mini-dystrophin–expressing myotubes.
Interaction between RYR-dependent 
and IP3R-dependent Releases?
Given that the exposure to a mixture of 2-APB and 
  ryanodine almost abolished the K+-evoked calcium 
  increase, it was surprising to observe that the sum of 
releases, induced by separate applications of the two 
compounds, did not result in the release observed in 
the controls (Fig. 1, B and C, and Fig. 2), particularly 
in SolC1(−). Furthermore, increase kinetics (with re-
spect to TTP and IS) were similar in controls and in 
cells exposed to 2-APB, suggesting that the fast release 
from RYRs was unchanged in both conditions. It is 
well known that release from IP3Rs strongly depends 
on intracellular calcium concentrations, leading to a 
calcium-induced calcium release (CICR) with high 
levels of Ca2+ (Berridge, 1993). It is possible that in 
control conditions, calcium ions initially released from 
RYRs may activate IP3Rs and then amplify the slow re-
lease mediated by the IP3 pathway. The IP3-dependent 
release observed in the presence of ryanodine is thus 
reduced as compared with control conditions, particu-
larly in SolC1(−) in which the IP3-dependent release 
is pronounced.
Inhibitory Effect of Mini-dystrophin in the IP3 
Production Pathway
Liberona et al. (1998) previously observed that in dys-
trophic cells, basal levels of IP3 mass were three to six-
fold higher than in their normal counterparts. Moreover, 
other studies demonstrated increased IP3 mass with de-
polarization, showing that the level of IP3 mass in cul-
tured muscle cells could be regulated by membrane 
potential, through the α-1 subunit of the DHPR (Araya 
et al., 2003) and by muscarinic acetylcholine receptors 
(Reyes and Jaimovich, 1996). Our experiments, com-
bined with this data, lead us to think that IP3 production 180 IP3 Receptors and Dystrophin-deﬁ  cient Cells
after membrane depolarization is signifi  cantly elevated 
in dystrophin-defi  cient myotubes and that the presence 
of mini-dystrophin under the membrane leads to re-
duced IP3 production.
The mechanism by which membrane depolarization 
induces the activation of PLC to produce IP3 has not 
been established. Specifi   c G protein βγ dimers are 
thought to mediate the regulation of PLC activity in 
some cases (Kanthou et al., 1996) and it was proposed 
that in skeletal muscle, the voltage sensor DHPR could 
directly or indirectly be linked to a protein of the Gi 
type, which in turn activates a PLC (Araya et al., 2003). 
The results obtained here with PTX on depolarization-
evoked calcium release demonstrate a strong reduction 
in calcium release that was more pronounced in 
SolC1(−) than in SolD(+). We then suggest an inhibi-
tory effect of mini-dystrophin at that level and propose 
a hypothetical model of the effect of mini-dystrophin 
on IP3 production (Fig. 7). During membrane depolar-
ization, DHPRs could both activate the release from 
RYRs (fast release) and enhance the activity of PLC 
through a Gi protein. This enhanced activity leads to an 
increase in IP3 concentration in the cytoplasm and in-
duces calcium release from IP3Rs (slow release) (Fig. 
7 A). The presence of mini-dystrophin under the mem-
brane could result in a reduction of PLC activity at the 
level of PLC, or upstream of the Gi protein (Fig. 7 B). 
Concerning the possible link between mini-dystrophin 
and these proteins, the binding between heterotrimeric 
G proteins and syntrophin (a cytoskeletal protein known 
to interact with dystrophin) has been demonstrated in 
skeletal muscle cells (Zhou et al., 2005). These scaffold-
ing proteins involved in the protein network under the 
membrane could have modulatory effects on signaling 
activities. One can postulate that a negative protein–
protein interaction involving these scaffolding proteins 
could be restricted to the submembrane area where this 
complex is located. Nevertheless, if IP3 production is 
reduced, a reduced Ca2+ release will follow, and the 
consequences of the negative interaction could be 
propagated inwards through the reduction of the dif-
fusible CICR mechanism. Conversely, the absence of 
dystrophin may have the opposite effect in enhancing 
the CICR mechanism, even in thicker structures, such 
as adult muscle fi  bers.
Three main fi  ndings are of particular interest in this 
work: fi  rst, this study indicates a possible role of Ca2+ re-
lease from the SR in Ca2+ mishandling in dystrophin-
defi  cient cells. Specifi  cally, our results strongly support 
the hypothesis of increased Ca2+ release in dystrophin-
defi  cient myotubes, leading to calcium deregulation. 
Second, this deregulation can be attenuated with mini-
dystrophin expression (a candidate for gene therapy). 
Finally, this work shows evidence for a major role of 
the IP3 pathway in Ca2+ release during stimulation in 
  dystrophin-defi  cient myotubes.
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